Thomas J. Ettrich
YOU?
Author Swipe
View article: Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial Open
Perioperative treatment strategies for HER2-positive esophagogastric adenocarcinoma remain suboptimal. Here in the open-label, phase 2 IKF/AIO PHERFLOT trial, we evaluated the safety and efficacy of adding pembrolizumab and trastuzumab to …
View article: Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216) Open
EudraCT: 2016-005147-17; ClinicalTrials.gov: NCT03468335.
View article: Interest in complementary and alternative medicine among participants in a study on cancer prevention by green tea extract – results from an expert-based survey of MIRACLE trial participants
Interest in complementary and alternative medicine among participants in a study on cancer prevention by green tea extract – results from an expert-based survey of MIRACLE trial participants Open
Objective Although chemopreventive strategies such as acetylsalicylic acid have shown potential in cancer prevention, they also entail adverse effects. This leads to growing interest in “natural” compounds, such as plant-based extracts, wh…
View article: Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial) Open
Introduction Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objec…
View article: 18O Machine learning-based liquid biomarker signatures for predicting success of perioperative and adjuvant chemotherapy in resectable PDAC: Translational data from the NEONAX trial
18O Machine learning-based liquid biomarker signatures for predicting success of perioperative and adjuvant chemotherapy in resectable PDAC: Translational data from the NEONAX trial Open
View article: Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study
Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study Open
Background & Aims Cholangiocarcinoma (CCA) is a rare cancer with limited therapeutic options and a poor prognosis. While first‐line combination therapies have improved outcomes, second‐line treatment remains challenging. Ivosidenib, an IDH…
View article: Supplementary Table S1 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Supplementary Table S1 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Representativeness of study participants
View article: Data from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Data from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Purpose:We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer.Patients and Methods:This was a phase III, prospectiv…
View article: Supplementary Table S2 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Supplementary Table S2 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Impact on disease-free survival by number of tablets taken per day in Cox regression analysis
View article: Supplementary Figure S1 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Supplementary Figure S1 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Sensitivity analyses accounting for non-proportional hazards. Sensitivity analyses accounting for non-proportional hazards using restricted mean survival time. The separating curves over time indicate the benefit of aspirin over placebo on…
View article: Supplementary Table S3 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Supplementary Table S3 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Recurrence-free rates including 90% confidence intervals at different time points
View article: Supplementary Figure S2 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Supplementary Figure S2 from Adjuvant Aspirin Treatment in <i>PIK3CA</i>-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Overall survival. Kaplan-Meier curve of overall survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue).
View article: An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial Open
Background Prognosis in advanced pancreatic ductal adenocarcinoma (aPDAC) is particularly poor, only few patients benefit from treatment, and there are few biomarkers. The PREDICT trial examined whether first-line time-to-treatment failure…
View article: 407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial
407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial Open
View article: 174P A phase II, non-randomized, single-arm, translational study of cabozantinib for patients with hepatocellular carcinoma (HCC) refractory to first-line treatment (the IKF-t018 AURORA trial)
174P A phase II, non-randomized, single-arm, translational study of cabozantinib for patients with hepatocellular carcinoma (HCC) refractory to first-line treatment (the IKF-t018 AURORA trial) Open
View article: Impact of preoperative radiotherapy on patient‐reported outcomes in rectal cancer
Impact of preoperative radiotherapy on patient‐reported outcomes in rectal cancer Open
Aim To prospectively evaluate the effect of preoperative radiotherapy followed by surgery versus surgery alone on patient‐reported outcomes (PROs) 1 year after surgery. Method Prospective observational cohort study in 127 colorectal cancer…
View article: 357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial
357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial Open
View article: CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism
CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism Open
Introduction: Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 mon…
View article: Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution
Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Open
SUMMARY Patient-derived organoids (PDOs) reflect parental tumor features and may represent promising avatars for prognosticating drug response. Here, we recruited 169 patients with pancreatic cancer (PC) and established a living biobank in…
View article: PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer Open
Summary De novo or acquired resistance to chemotherapy is ubiquitous in pancreatic ductal adenocarcinoma (PDAC). SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver …
View article: Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study Open
Background/Objectives: Systemic treatment for unresectable hepatocellular carcinoma (HCC) has rapidly advanced, with immune checkpoint inhibitors now the preferred first-line option. However, with multiple agents available and no establish…
View article: Adjuvant Aspirin Treatment in <i>PIK3CA</i> -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial
Adjuvant Aspirin Treatment in <i>PIK3CA</i> -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial Open
Purpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer. Patients and Methods: This was a phase III, prospective, r…
View article: Supplementary Figure 2 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 2 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy Open
Supplementary Figure 2: Emotional distress and tumor burden do not explain the systemic inflammatory signature.
View article: Supplementary Figure 3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy Open
Supplementary Figure 3: Low NLR defines patients with superior survival in the Ipi arm.
View article: Supplementary Tables 1-3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Tables 1-3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy Open
Supplementary Tables 1-3
View article: Data from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Data from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy Open
Anti–PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma, but long-term survival remains limited. In this study, we report extended follow-up data from the IN…
View article: Supplementary Figure 1 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 1 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy Open
Supplementary Figure 1: The duration of response to various therapy lines for patients in the Ipi arm is depicted. For each line of therapy, the duration of response (DOR) is indicated if applicable. Active therapy is represented by an arr…
View article: Supplementary Figure 4 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 4 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy Open
Supplementary Figure 4: PFS in selected patients and overall survival of NLR > 5 patients. (A) PFS in months is shown for patients selected by CPS ≥ 1, HER2-3+, and NLR < 5 within the Ipi arm (n=12). Median PFS was 20.9 months. (B) Final o…
View article: Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab Open
The CABLE score allows estimation of the prognosis of patients with unresectable hepatocellular carcinoma undergoing first-line immunotherapy with atezolizumab and bevacizumab at an individual level using our web-based calculator. This fea…
View article: Organoid‐based precision medicine in pancreatic cancer
Organoid‐based precision medicine in pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) ranks among the leading causes of cancer‐related deaths worldwide. Despite advances in precision oncology in other malignancies, treatment of PDAC still largely relies on conventional chemotherapy. G…